Microbiotica is using best-in-class clinical data and sample sets coupled with its unrivalled microbiome profiling capability to progress best-in-class therapeutics and biomarkers.

Microbiotica has programs in IBD, Immuno-oncology and Gut Epithelial Barrier Repair developing medicines and biomarkers based on microbiota. These programs start with deep metagenomic and culture-based analysis of patient samples and involve advanced bioinformatics and machine learning, to identify highly significant bacterial signatures linked to phenotype. The signatures represent both biomarkers and Live Bacterial Therapeutics. Live Bacterial Therapeutics are progressed in advanced human in vitro and in vivo models before process development, including high throughput growth optimisation and developability screening, to generate products for manufacture and clinical testing.